Table 3. . Bivariate and multivariate analyses for overall survival.
| Characteristics | Category | Univariate |
Multivariate | |
|---|---|---|---|---|
| p-value | HR (95% CI) | p-value | ||
| Age | ≥48 vs <48 years | 0.361 | – | – |
| Parity | Multiparous vs nulliparous | 0.029 | 1.96 (0.95–4.05) | 0.069 |
| Menopausal status | Postmenopause vs premenopause | 0.800 | – | – |
| BMI | ≥24.0 vs <24.0 kg/m2 | 0.664 | – | – |
| Serum CA-125 levels | ≥114.0 vs <114.0 U/ml | 0.548 | – | – |
| Comorbidity | Yes vs No | 0.742 | – | – |
| Upfront primary treatment | NACT and IDS vs PDS | 0.657 | – | – |
| Ascites | Yes vs no | 0.359 | – | – |
| FIGO stage | Advanced vs early | 0.506 | – | – |
| Residual disease status | Optimal vs suboptimal | 0.947 | – | – |
| Histologic subtype | Type II vs Type I | 0.574 | – | – |
| Pretreatment NLR | ≥649.0 vs <649.0 × 109 cells/l | 0.019 | 2.01 (1.01–3.99) | 0.046 |
BMI: Body mass index; CA: Cancer antigen; FIGO: International Federation of Gynecology and Obstetrics; HR: Hazard ratio; IDS: Interval debulking surgery; NACT: Neoadjuvant chemotherapy; PDS: Primary debulking surgery; Type I includes endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, and low-grade serous carcinomas; Type II includes high-grade serous carcinomas; SII: Systemic immune-inflammation index.